Skip to main content

Advertisement

ADVERTISEMENT

News

News
10/07/2024
The pulmonary arterial hypertension drug market is projected to grow to $11.6 billion by 2032, driven by an increase in pulmonary disorders, advancements in treatment options, and greater awareness of the condition.
The pulmonary arterial hypertension drug market is projected to grow to $11.6 billion by 2032, driven by an increase in pulmonary disorders, advancements in treatment options, and greater awareness of the condition.
The pulmonary arterial...
10/07/2024
First Report Managed Care
News
10/07/2024
Mortality was significantly higher among post-9/11 military veterans with epilepsy who had a traumatic brain injury (TBI) before epilepsy or who experienced a TBI within 6 months of their epilepsy diagnosis, according to a study published...
Mortality was significantly higher among post-9/11 military veterans with epilepsy who had a traumatic brain injury (TBI) before epilepsy or who experienced a TBI within 6 months of their epilepsy diagnosis, according to a study published...
Mortality was significantly...
10/07/2024
First Report Managed Care
News
10/04/2024
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New...
10/04/2024
First Report Managed Care

Advertisement

News
09/27/2024
Harvard Medical School researchers unveil a potentially groundbreaking AI tool, TxGNN, that identifies potential drug candidates for 17 080 diseases, offering hope for patients with rare and neglected conditions.
Harvard Medical School researchers unveil a potentially groundbreaking AI tool, TxGNN, that identifies potential drug candidates for 17 080 diseases, offering hope for patients with rare and neglected conditions.
Harvard Medical School...
09/27/2024
First Report Managed Care
News
09/27/2024
A study published in the Annals of Clinical Microbiology and Antimicrobials explores the impact of multidrug-resistant (MDR) bacterial infections on the clinical outcomes of adult patients with bronchiectasis, finding a significant increase...
A study published in the Annals of Clinical Microbiology and Antimicrobials explores the impact of multidrug-resistant (MDR) bacterial infections on the clinical outcomes of adult patients with bronchiectasis, finding a significant increase...
A study published in the Annals...
09/27/2024
First Report Managed Care
News
09/25/2024
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based...
09/25/2024
First Report Managed Care

Advertisement

News
09/23/2024
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive...
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive...
A study published in JAMA...
09/23/2024
First Report Managed Care
News
09/23/2024
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology...
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology...
Recent data has established...
09/23/2024
First Report Managed Care
News
09/23/2024
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor...
09/23/2024
First Report Managed Care

Advertisement

News
09/20/2024
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking...
09/20/2024
First Report Managed Care

Advertisement